Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.

Newest Combination HIV Antigen-Antibody Assay Evaluated

By Labmedica International staff writers
Posted on 27 Feb 2013
Diagnostic tests capable of early detection represent the most effective means of preventing transmission of human immunodeficiency virus (HIV).

A fourth-generation antigen-antibody combination assay has been developed to allow earlier detection of seroconversion, and has increased sensitivity and improved specificity.

Scientists at the Innsbruck University Hospital (Austria) determined how early the assay could detect infection compared with existing assays; whether all HIV variants could be detected; and the assay's specificity using samples from blood donors, routine specimens, and patients with potential cross-reacting factors.

The study was carried out at 12 centers in Europe, Thailand, and Australia. The Elecsys HIV combi PT assay (Roche Diagnostics; Penzberg, Germany) is performed according to the sandwich principle. The results are automatically determined by the Elecsys software that compares the signal produced from the sample with the cutoff value obtained during system calibration. The total assay time is 27 minutes.

A total of 14 seroconversion panels, comprising 135 samples were analyzed to determine how soon after a positive polymerase chain reaction (PCR) result the immunoassays could detect HIV infection. Samples were identified as positive by the Elecsys assay 4.9 days after a positive PCR result that had been predetermined, which was earlier than the 5.3 to 7.1days observed with other comparable assays. The analytical sensitivity of the Elecsys HIV combi PT assay for the HIV-1 p24 antigen was 1.05 IU/mL, which compares favorably with the other assays.

In addition, the assay identified all screened HIV subtypes and displayed greater sensitivity to HIV-2 homologous antigen and antibodies to HIV-1 E and O and HIV-2 than the other assays. The assay demonstrated 100% specificity in patients with infections other than HIV, such as Cytomegalovirus or herpes simplex virus. Overall, the specificity of the Elecsys assay was 99.88% using samples from blood donors and 99.81% when analyzing unselected samples. Potential cross-reacting factors did not interfere with assay performance. The Elecsys HIV combi PT assay has been granted the European Conformity (CE) marking and is now available for use in laboratory-based testing. The study was published in the February 2013 issue of the journal Medical Microbiology and Immunology.

Related Links:
Innsbruck University Hospital
Roche Diagnostics


Dubai Bio Expo-2015
KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.